Skip directly to content

Implementing improvements for the management of Atrial Fibrillation

The information on this page about a Quality Improvement Grant call for applications programme (posted by the BMS-Pfizer Alliance) is intended for healthcare audiences only. Information on Quality Improvement grant call for applications is not intended for members of the public and the information shared is only applicable to healthcare institutions, organisations and associations, or equivalent.

Pfizer, on behalf of the BMS-Pfizer Alliance, is now inviting UK healthcare organisations to submit a grant proposal for a Quality Improvement Grant, which will support a project that has a focus on implementing improvements for the management of atrial fibrillation in the United Kingdom.


Quality Improvement Grants are intended to either enhance patient care or benefit the NHS and maintain patient care. They cannot be linked to the prescribing or use of a specific medicine. As a result, the BMS-Pfizer Alliance’s involvement is strictly limited to the arm’s length provision of the Quality Improvement grant and we do not receive any direct benefit in return.

Atrial Fibrillation (AF) is a major cause of preventable stroke and the prevalence is projected to rise substantially over the next few decades with our ageing population.1 Despite the availability of effective oral anticoagulation therapy, atrial fibrillation continues to be responsible for substantial mortality and morbidity.2 During this challenging time, there may have been decreased opportunities for the management of AF, due to fewer patients visiting surgeries than before the COVID-19 pandemic.

The BMS-Pfizer Alliance wishes to provide funding for appropriate, competitively reviewed and judged applications, which enable healthcare organisations to implement important local patient focused improvements in the management of AF.

Applying healthcare organisations must be legal entities in their own right, not individual healthcare professionals or single medical practices. For example, the following may apply: Primary Care Networks, Clinical Commissioning Groups, Health Boards or equivalent.

Applications for projects requesting funding support of up to £25k will be considered. Funding requests must be for the implementation of suitable improvements for AF management. The total available budget related to this project is £300k.


We are interested in receiving applications that include the following:

  • Projects that focus on implementing improvements for the management of atrial fibrillation
  • Projects intended to support an independent medical and/or scientific initiative of that healthcare organisation, intended for quality improvement and improvements in patient outcomes, in an area of unmet medical need
  • Projects that include both a named project lead and deputy, or two named co-leads, to help ensure project continuity should a named project lead leave the organisation
  • Projects that include a letter of support from the organisation, to demonstrate organisational prioritisation of this project and organisational capacity for implementation


Proposals for projects covering the following areas are out of scope of this call:

  • Projects bearing the name or class of specific medicines
  • Projects designed to increase the uptake of a single therapeutic agent or intervention (projects should be aimed at improving adherence to specific guidelines or patient pathways)
  • Applications for funding of services which should be provided as standard within the NHS
  • Applications including funding for capital expenses E.g. Computers, iPhones, tablets, appliances, machinery, camera equipment, sensors
  • Interventional or observational studies
  • In vitro or in vivo (animal) studies
  • Non-interventional studies, such as epidemiological studies
  • Outcomes research studies where the primary focus is to understand the results of particular healthcare practices and interventions as well as to monitor and improve the quality of care
  • Other types of independent research on disease states, including novel diagnostic screening tools and surveys


Pfizer, on behalf of the BMS-Pfizer Alliance, processes these applications through the Pfizer Global Medical Grants System.

For all independent grants, the grant requester and the healthcare organisation grantee are responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements. Pfizer must not be involved in any aspect of the project development, nor the conduct or monitoring of the initiative. At the end of the project, all successful Grant Recipients will be expected to provide the BMS-Pfizer Alliance with a short, high level information summary report on the effectiveness of the project, such as outcomes for patients and the NHS.


Applying for Management of Atrial Fibrillation Quality Improvement Grant

This is a Competitive Grant Programme which uses an internal Pfizer panel to make final grant decisions, based on the panel’s evaluation of the proposal and the costs involved set out in the Management of Atrial Fibrillation ‘Call for Proposals’.


To contact Pfizer for any other purpose, including adverse event reporting, medical information requests, or data protection enquiries please call 01304 616161.



  1. Krijthe BP, Kunst A, Benjamin EJ, et al. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur Heart J.2013;34(35):2746-2751.
  2. James SL, Abate D, Abate KH, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet. 2018;392(10159):1789-1858.



PP-INT-GBR-0335 / June 2021